New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
06:06 EDTIMUCImmunoCellular allows IND for ICT-140
ImmunoCellular Therapeutics announced that the FDA has allowed the investigational new drug, or IND, application for ICT-140, paving the way for conducting a clinical trial. ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer stem cells. ImmunoCellular filed the IND application with the FDA in the Q4 of FY12, as planned.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2016
06:04 EDTIMUCImmunoCellular enters into sponsored research agreement with Eduardo Davila, PhD
ImmunoCellular announced it has entered into a sponsored research agreement with Eduardo Davila, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and the University of Maryland, Baltimore. The agreement includes three projects, which together have the potential to improve the efficacy of dendritic cell, T-cell, and combination immunotherapies for cancer and lead to enhancements to both of ImmunoCellular's dendritic cell and Stem-to-T-cell platforms.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use